Comment

Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced today a strategic alliance to collaborate on the development and commercialization of biological therapeutics in China and with potential international expansion.

Comment

Comment

Scientific Publication by a Group Including Juno Therapeutics Scientific Co-Founder Michel Sadelain Is Featured in Endpoints News Article

CAR-Ts won’t be on the market before next year, but the technology arms race inspired by the prospect of a multibillion-dollar market has inspired a group of prominent investigators to design a new, 3.0 model in the lab that includes a built-in checkpoint mechanism. And it worked like a charm in mouse models of solid tumors - a critical hurdle that the key players have been struggling to clear.

Comment

Comment

FDA Accepts ADMA Biologics License Application for RI-002

ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for RI-002 intended for the primary immunodeficiency (PI) population.

Comment

Comment

JHL Biotech Successfully Raises $45.6 Million Series C Financing

JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.

Comment

Comment

HCG announces new standard-of-care for cancer treatment in India

HealthCare Global (HCG) Enterprises Ltd, The Specialists in Cancer Care, creates a new benchmark in cancer care by making genomics-based diagnostics, a standard-of-carefor cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for actionablemutations. The information about these mutations helps to identify targeted therapies and treatment choices early in the course of cancer care. 

Comment

Comment

Curie-Cancer and Strand launch Curie Image Database

Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activity, and Strand Scientific Intelligence, Inc. (Strand) announce the launch of the Curie Image Database (CID), a breakthrough image analysis and management platform that they developed jointly over the last two years at the Cell and Tissue Imaging Core Facility of the Institut Curie (PICT-IBiSA). 

 

Comment

Comment

Strand Life Sciences to partner with US based El Camino Hospital to set up Strand Center for Genomics and Personalized Medicine

Strand Life Sciences Private Limited, a global life sciences company headquartered in Bangalore, is collaborating with the San Francisco Bay Area based El Camino Hospital to locate a Strand Center for Genomics and Personalized Medicine at the Genomic Medicine Institute of the El Camino Hospital to accelerate the adoption of next generation sequencing based research panels and counseling services by the physicians at the Hospital and its partner clinics. 

 

Comment

Comment

Why Strand Life Sciences wants doctors to genetically profile patients

Strand Life Sciences, a bioinformatics company whose products for Array, Mass Spec and NGS analysis are used by over 2000 laboratories worldwide and has recently developed solutions in the field of clinical diagnostics, is launching its Early Access Program for its clinical genomics interpretation and reporting platform. Strand’s clinical application is a deep interpretation and reporting system for clinical genomics.  It was designed in collaboration with clinicians while working on real patient cases in Strand’s clinical laboratory, and therefore provides the necessary information to help medical practitioners confidently deliver clinical reports with ease.

Comment